| Writing group member | Employment | Research grant | Other research support | Speakers’ bureau/honoraria | Expert witness | Ownership interest | Consultant/advisory board | Other |
|---|---|---|---|---|---|---|---|---|
| Aarti Asnaniǂ | Beth Israel Deaconess Medical Center and Harvard Medical School Cardiovascular Institute | NIH/NHLBI K08HL145019†; R21HL148748† | None | None | None | None | Cytokinetics* | None |
| Javid J. Moslehi | Vanderbilt University Medical Center | NIH/NHLBI R01HL141466†; R01HL155990†; R01HL156021 † | None | None | None | None | Amgen*; AstraZeneca*; Audentes Pharmaceuticals*; Boehringer*; Boston Biomedical*; Bristol-Myers Squibb†; Cytokinetics*; Deciphera*; GlaxoSmithKline*; GSK*; ImmunoCore*; Janssen*; Myovant*; Nektar*; Pfizer* Pharmacyclics*; Regeneron*; Takeda* | None |
| Bishow B. Adhikari | National Institutes of Health, NHLBI | None | None | None | None | None | None | None |
| Alan H. Baik | University of California, San Francisco | None | None | None | None | None | None | None |
| Andreas M. Beyer | Medical College of Wisconsin | NIH (R01 level funding to support ongoing research laboratory)†; Bayer Pharmaceutical (contract to test efficacy of new drug in human source material, no personal gain or salary support)*; other academic investigators (reagents, tools, and compounds for research use)* | None | None | None | None | None | None |
| Rudolf A. de Boer | University Medical Center Groningen (The Netherlands) | DELIVER study (dapagliflozin in HFpEF) (executive board member [unpaid])*; MONITOR HF study (PA pressure monitoring in severe heart failure) (co-PI [unpaid])*; European Research Council, CoG 818715 (unpaid)* | None | None | None | None | None | None |
| Alessandra Ghigo | University of Torino (Italy) | None | None | None | None | None | None | None |
| Isabella M. Grumbach | University of Iowa | NIH (research grant to study vascular toxicity)† | None | None | None | None | None | None |
| Salvia Jain | Beth Israel Deaconess Medical Center | Abcuro, Inc. (research funding was obtained from company)†; NCI (K08 Career Development Grant was obtained)† | None | None | None | None | None | Abcuro, Inc. (0.2% salary support is being provided by Abcuro)*; NCI (K02 Career Development Grant)† |
| Han Zhu | Stanford University | None | None | None | None | None | None | None |
This table represents the relationships of writing group members that may be perceived as actual or reasonably perceived conflicts of interest as reported on the Disclosure Questionnaire, which all members of the writing group are required to complete and submit. A relationship is considered to be “significant” if (a) the person receives $10 000 or more during any 12-month period, or 5% or more of the person’s gross income; or (b) the person owns 5% or more of the voting stock or share of the entity or owns $10 000 or more of the fair market value of the entity A relationship is considered to be “modest” if it is less than “significant” under the preceding definition.
Modest.
Significant.
Dr. Asnani took on a Consulting position at Cytokinetics after acceptance of this manuscript and with the approval of the AHA. Since then, she has not made any edits to the manuscript other than responses to author queries.